Innocoll Announces Dosing Of First Patient In Second US Phase 3 Clinical Trial To Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT
Feb 26th 2008Drug InformationInfectious Diseases / Bacteria / Viruses
Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the second of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections, has commenced dosing.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
